Factors Associated With Antipsychotic Polypharmacy and High-Dose Antipsychotics Among Individuals Receiving Compulsory Treatment in the Community

被引:10
|
作者
Gisev, Natasa [1 ]
Bell, J. Simon [2 ,3 ,4 ]
Chen, Timothy F. [1 ]
机构
[1] Univ Sydney, Fac Pharm, Sydney, NSW 2006, Australia
[2] Monash Univ, Ctr Med Use & Safety, Fac Pharm & Pharmaceut Sci, Parkville, Vic, Australia
[3] Univ Eastern Finland, Fac Hlth Sci, Sch Pharm, Kuopio, Finland
[4] Univ S Australia, Sansom Inst, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia
关键词
antipsychotic agents; commitment of mentally ill; community mental health services; drug utilization; logistic models; LONG-ACTING INJECTIONS; TREATMENT ORDERS; SCHIZOPHRENIA; CLOZAPINE; DRUGS; AUGMENTATION; TOLERABILITY; PREVALENCE; KNOWLEDGE; ATTITUDES;
D O I
10.1097/JCP.0000000000000098
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Community treatment orders (CTOs) are a form of compulsory treatment of individuals with a mental illness in the community. The objectives of this study were to determine the demographic, clinical, and treatment plan factors associated with antipsychotic polypharmacy and high-dose antipsychotics among individuals issued with a CTO. This was a secondary analysis of all 377 individuals who were prescribed an antipsychotic, extracted from a retrospective study of 378 individuals issued with a CTO by the New South Wales Mental Health Review Tribunal in Australia in 2009. Deidentified information relating to individuals' treatment plans, demographic, and clinical details were systematically extracted. Of the 377 individuals, 121 (32%) were prescribed antipsychotic polypharmacy and 101 (27%) high-dose antipsychotics. Unadjusted and adjusted odds ratios (ORs) and 95% confidence intervals (95% CIs) for factors associated with antipsychotic polypharmacy and high-dose antipsychotics were computed using binary logistic regression. There was a strong association between the use of antipsychotic polypharmacy and high-dose antipsychotics (P < 0.001). Only treatment plan factors were associated with antipsychotic polypharmacy and high-dose antipsychotics in adjusted models. Although first-generation long-acting injectable antipsychotics and clozapine were associated with antipsychotic polypharmacy (adjusted OR, 9.12; 95% CI, 4.21-19.74; adjusted OR, 7.97; 95% CI, 2.93-21.72), oral second-generation antipsychotics and risperidone long-acting injection were associated with high-dose antipsychotics (adjusted OR, 5.67; 95% CI, 2.89-11.12; adjusted OR, 8.14; 95% CI, 3.22-20.53). Therefore, the use of antipsychotic polypharmacy and high-dose antipsychotics among individuals issued with CTOs is associated only with the drugs prescribed in their treatment plans and not their individual demographic and clinical characteristics.
引用
下载
收藏
页码:307 / 312
页数:6
相关论文
共 50 条
  • [41] High-dose fluconazole for the treatment of Cryptococcal meningitis in HIV-infected individuals
    Larsen, R. A.
    Hollabaugh, K.
    Lalloo, U. G.
    Ssemmanda, M. M.
    Momanyi, L. M.
    Lagat, D. K.
    Hakim, J. G.
    Ly, T. T.
    Hogg, E.
    Komarow, L.
    Aberg, J. A.
    MYCOSES, 2014, 57 : 51 - 51
  • [42] Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate
    Drost, Sarah A.
    Wentzell, Jason R.
    Giguere, Pierre
    McLurg, Darcy L.
    Sabloff, Mitchell
    Kanji, Salmaan
    Nguyen, Tiffany T.
    PHARMACOTHERAPY, 2017, 37 (06): : 684 - 691
  • [43] Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
    C Dumontet
    S Landi
    T Reiman
    T Perry
    A Plesa
    I Bellini
    R Barale
    L M Pilarski
    J Troncy
    S Tavtigian
    F Gemignani
    Bone Marrow Transplantation, 2010, 45 : 1316 - 1324
  • [44] Genetic polymorphisms associated with outcome in multiple myeloma patients receiving high-dose melphalan
    Dumontet, C.
    Landi, S.
    Reiman, T.
    Perry, T.
    Plesa, A.
    Bellini, I.
    Barale, R.
    Pilarski, L. M.
    Troncy, J.
    Tavtigian, S.
    Gemignani, F.
    BONE MARROW TRANSPLANTATION, 2010, 45 (08) : 1316 - 1324
  • [45] Can dose reduction be made in patients with allergic bronchopulmonary aspergillosis receiving high-dose omalizumab treatment?
    Korkmaz, Elif Tugce
    Aydin, Omur
    Mungan, Dilsad
    Sin, Betul Ayse
    Demirel, Yavuz Selim
    Bavbek, Sevim
    EUROPEAN ANNALS OF ALLERGY AND CLINICAL IMMUNOLOGY, 2024, 56 (01) : 26 - 33
  • [46] RECOVERY FROM TOXICITY ASSOCIATED WITH HIGH-DOSE METHOTREXATE - PROGNOSTIC FACTORS
    CHAN, H
    EVANS, WE
    PRATT, CB
    CANCER TREATMENT REPORTS, 1977, 61 (05): : 797 - 804
  • [47] Prevalence, trends, and factors associated with antipsychotic polypharmacy among medicaid-eligible schizophrenia patients, 1998-2000
    Ganguly, R
    Kotzan, JA
    Miller, LS
    Kennedy, K
    Martin, BC
    JOURNAL OF CLINICAL PSYCHIATRY, 2004, 65 (10) : 1377 - 1388
  • [48] CHANGES OF STAPEDIUS REFLEX AND HEARING THRESHOLD IN PATIENTS RECEIVING HIGH-DOSE CISPLATIN TREATMENT
    LAURELL, G
    SKEDINGER, M
    AUDIOLOGY, 1990, 29 (05): : 252 - 261
  • [49] Costs per Treatment Phase for AML Patients Receiving High-Dose Chemoterapy in Sweden
    Hernlund, Emma
    Redig, Josefine
    Derolf, Asa Rangert
    Paulsson, Bjorn
    Hoglund, Martin
    Vertuani, Simona
    Juliusson, Gunnar
    BLOOD, 2019, 134
  • [50] A REVIEW OF ANTIPSYCHOTIC POLYPHARMACY, HIGH-DOSE PRESCRIBING AND EVALUATION OF ADHERENCE TO LOCAL PHYSICAL HEALTH MONITORING GUIDELINES, WITHIN THE ASSERTIVE COMMUNITY TEAM (ACT) AT ROCKINGHAM KWINANA MENTAL HEALTH SERVICE
    Vecchio, D.
    Spence, C.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2014, 48 : 125 - 126